BACKGROUND: Management of @entity1860 has changed markedly since the introduction of @entity669 kinase inhibitors (TKIs). However @entity8 ( @entity8 ) remains a valid therapeutic modality especially in developing countries due to its relatively lower cost. We aim to compare between @entity2213 and @entity8 as regard outcome in @entity1860 in the pediatric age group. METHODS: Forty-eight @entity1 with newly diagnosed @entity1860 in the chronic phase, aged 3 to 18 years were enrolled in this prospective study. @entity1 without a matched donor (Group I; N=30) were assigned to receive @entity2213 at a dose of 340mg  m2  day, while @entity1 with a fully matched related donor (Group II; N=18), were offered @entity8 . Response (hematologic, cytogenetic and molecular), side effects and survival were analyzed. RESULTS: Complete hematologic response was obtained in 97% of the @entity1 in group I and 94% in group II. Major cytogenetic response (CyR) was obtained in 80% of @entity1 in group I and 100% in group II. Complete CyR was 57% in group I and 64% in group II. Major molecular response (MMR) was 36% in group I and 50% in group II with no significant difference between both groups. Six years @entity1349 ( @entity1349 ) was 87% in the 1st group and 61% in the 2nd group (p<0.01), while eventfree survival (EFS) was 66% in the 1st group and 50% in the 2nd group with a highly significant difference between both groups (p<0.01). Side effects were generally rare and mild in the @entity2213 arm, while adverse events were more severe and common in the @entity8 group (55% had GVHD and 78% had @entity281 ). CONCLUSION: @entity2213 has a superior @entity1349 and EFS than @entity8 in @entity1 . It is generally safe and well tolerated. @entity2213 should be the 1st line treatment of pediatric @entity1 with @entity1860 in the chronic phase. KEY WORDS: @entity1860 - @entity2213 - @entity8 - Pediatrics.

Management of XXXX in the Pediatric Age Group: @entity2213 or @entity8 .

@entity1 :: ('9606', 'Species') :: ['children', 'Patients', 'patients'] @entity8 :: ('MESH:D007674', 'Disease') :: ['SCT', 'stem cell transplantation'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection'] @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine'] @entity1860 :: ('MESH:D015464', 'Disease') :: ['CML'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival'] @entity2213 :: ('MESH:C097613', 'Chemical') :: ['imatinib', 'Imatinib mesylate', 'imatinib mesylate', 'Imatinib']
@entity1860 :: (MESH:D015464,Disease) :: ['CML']
